gip glp 1 agonist tirzepatide GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 Dual and Triple Gut Peptide

10.1038/nm.3128 46 KimE

While retatrutide and SAR441255 demonstrate significant potential, several important aspects must be addressed to fully optimize the clinical application of triple agonists

Long-acting dosage forms have more advantages in blood sugar control due to their longer half-life and stable blood concentration

68.Hamed K., Alosaimi M

In preclinical models, co-administration of bimagrumab or dual myostatin/activin A inhibitors with GLP-1R agonists preserves or increases muscle mass while enhancing fat loss, resulting in improved body composition and metabolic outcomes compared with GLP-1R agonist monotherapy [176]